Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $12.38

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned an average recommendation of “Buy” from the fourteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $12.6154.

A number of research analysts have recently commented on the stock. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Finally, BMO Capital Markets raised their price target on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $6.53 on Monday. Taysha Gene Therapies has a twelve month low of $2.33 and a twelve month high of $7.30. The stock has a market cap of $1.88 billion, a PE ratio of -17.18 and a beta of 1.17. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. The business’s 50-day moving average price is $6.14 and its 200-day moving average price is $5.33.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, equities analysts forecast that Taysha Gene Therapies will post -0.49 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP raised its stake in shares of Taysha Gene Therapies by 150.0% during the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock worth $75,625,000 after acquiring an additional 8,250,000 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $11,178,000. Barclays PLC boosted its stake in shares of Taysha Gene Therapies by 1,042.8% in the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at $20,471,000. Finally, State Street Corp grew its holdings in shares of Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.